NASDAQ:SANA Sana Biotechnology - SANA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.71 +0.15 (+3.29%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.44▼$4.7650-Day Range$3.19▼$4.9952-Week Range$3.15▼$9.60Volume1.01 million shsAverage Volume970,835 shsMarket Capitalization$898.34 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Sana Biotechnology MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside101.7% Upside$9.50 Price TargetShort InterestBearish32.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.81) to ($1.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.80 out of 5 starsMedical Sector836th out of 1,053 stocksBiological Products, Except Diagnostic Industry137th out of 170 stocks 3.3 Analyst's Opinion Consensus RatingSana Biotechnology has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Sana Biotechnology has a forecasted upside of 101.7% from its current price of $4.71.Amount of Analyst CoverageSana Biotechnology has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted32.36% of the float of Sana Biotechnology has been sold short.Short Interest Ratio / Days to CoverSana Biotechnology has a short interest ratio ("days to cover") of 26, which indicates bearish sentiment.Change versus previous monthShort interest in Sana Biotechnology has recently increased by 3.27%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSana Biotechnology does not currently pay a dividend.Dividend GrowthSana Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SANA. Previous Next 1.9 News and Social Media Coverage News SentimentSana Biotechnology has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sana Biotechnology this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SANA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sana Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders35.40% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.12% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sana Biotechnology are expected to grow in the coming year, from ($1.81) to ($1.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sana Biotechnology is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sana Biotechnology is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSana Biotechnology has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sana Biotechnology (NASDAQ:SANA) StockSana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.Read More Receive SANA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address SANA Stock News HeadlinesJanuary 26, 2023 | msn.comSana Biotechnology gains FDA IND clearance for CAR T therapy for B-cell malignanciesJanuary 26, 2023 | finance.yahoo.comSana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell MalignanciesFebruary 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 26, 2023 | benzinga.comMorgan Stanley Maintains Overweight on Sana Biotechnology, Lowers Price Target to $13January 26, 2023 | americanbankingnews.comSana Biotechnology (NASDAQ:SANA) Price Target Lowered to $13.00 at Morgan StanleyJanuary 24, 2023 | msn.comMorgan Stanley Maintains Overweight Rating for Sana Biotechnology: Here's What You Need To KnowJanuary 3, 2023 | finance.yahoo.comSana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 27, 2022 | msn.comBiotech industry leaders share cautious optimism for 2023 amid downturn and layoffsFebruary 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 11, 2022 | finance.yahoo.comSana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual MeetingDecember 1, 2022 | msn.comSana Biotechnology will cut 15% of its workforce in latest layoffs affecting Seattle companiesDecember 1, 2022 | finance.yahoo.comSana Biotechnology to lay off 15% of its employeesNovember 29, 2022 | finance.yahoo.comSana Biotechnology Confirms Key Program Timelines and Announces Portfolio PrioritizationNovember 15, 2022 | finance.yahoo.comSana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer CategoryNovember 4, 2022 | benzinga.comGoldman Sachs Maintains Neutral on Sana Biotechnology, Lowers Price Target to $6November 3, 2022 | finanznachrichten.deSana Biotechnology, Inc: Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business UpdatesNovember 3, 2022 | finance.yahoo.comSana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual MeetingNovember 2, 2022 | finance.yahoo.comSana Biotechnology Reports Third Quarter 2022 Financial Results and Business UpdatesSeptember 29, 2022 | msn.comMental health startup focused on seniors launches with $32M, backing from Arch Venture PartnersSeptember 13, 2022 | finance.yahoo.comNature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-UpSeptember 9, 2022 | finance.yahoo.comSana Biotechnology to Present at September 2022 Investor ConferencesSeptember 8, 2022 | nasdaq.comWe Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth CarefullySeptember 3, 2022 | finance.yahoo.comInsiders who bought in the last 12 months lose an additional US$22k as Sana Biotechnology, Inc. (NASDAQ:SANA) drops to US$1.2bAugust 11, 2022 | businessinsider.comThe economy is in a downturn, and top biotech VCs are favoring startups that can bring in revenue over companies chasing cool ideasAugust 4, 2022 | finance.yahoo.comSana Biotechnology Reports Second Quarter 2022 Financial Results and Business UpdatesJuly 12, 2022 | msn.comSpinning out science startups: UW’s Institute for Protein Design brings research beyond ivory towerJuly 9, 2022 | nasdaq.comSana Biotechnology Inc Shares Close the Week 35.6% Higher - Weekly WrapSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SANA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address SANA Company Calendar Last Earnings11/07/2021Today2/01/2023Next Earnings (Estimated)3/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SANA CUSIPN/A CIK1770121 Websana.com Phone206-701-7914FaxN/AEmployees383Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.50 High Stock Price Forecast$13.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+101.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-355,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.37% Return on Assets-38.02% Debt Debt-to-Equity RatioN/A Current Ratio4.36 Quick Ratio4.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.86 per share Price / Book1.22Miscellaneous Outstanding Shares190,730,000Free Float123,209,000Market Cap$898.34 million OptionableNot Optionable Beta0.60 Key ExecutivesDr. Steven D. Harr M.D. (Age 53)Pres, CEO & Director Comp: $1.19MDr. Richard C. Mulligan Ph.D. (Age 68)Exec. Vice Chairman & Head of SanaX Mr. Nathan Hardy M.B.A. (Age 47)Exec. VP & CFO Comp: $683.49kDr. Sunil Agarwal M.D. (Age 53)Exec. VP, Head of Devel. & Chief Medical Officer Comp: $728.45kBrittany MccleeryAccounting Mang.Dr. Edward Rebar Ph.D. (Age 55)Sr. VP & CTO Mr. Bernard J. Cassidy J.D. (Age 68)Exec. VP & Gen. Counsel Ms. Robin Andrulevich (Age 57)Exec. VP & Chief People Officer Mr. Paul Brunetta M.D.Sr. VP and Head of Clinical & Translational ScienceMs. Donna Dambach D.V.M.Ph.D., Sr. VP & Head of Devel. SciencesMore ExecutivesKey CompetitorsNovavaxNASDAQ:NVAXValnevaNASDAQ:VALNAnavex Life SciencesNASDAQ:AVXLExscientiaNASDAQ:EXAIAgenusNASDAQ:AGENView All CompetitorsInsiders & InstitutionsZurcher Kantonalbank Zurich Cantonalbank Bought 2,963 shares on 2/1/2023Ownership: 0.006%Clarius Group LLCBought 34,325 shares on 1/25/2023Ownership: 0.025%Baillie Gifford & Co.Sold 202,009 shares on 1/24/2023Ownership: 5.644%Bank of New York Mellon CorpBought 62,182 shares on 12/8/2022Ownership: 0.195%Bridgefront Capital LLCBought 10,475 shares on 11/29/2022Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions SANA Stock - Frequently Asked Questions Should I buy or sell Sana Biotechnology stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SANA shares. View SANA analyst ratings or view top-rated stocks. What is Sana Biotechnology's stock price forecast for 2023? 2 equities research analysts have issued 1-year price targets for Sana Biotechnology's stock. Their SANA share price forecasts range from $6.00 to $13.00. On average, they expect the company's share price to reach $9.50 in the next year. This suggests a possible upside of 101.7% from the stock's current price. View analysts price targets for SANA or view top-rated stocks among Wall Street analysts. How have SANA shares performed in 2023? Sana Biotechnology's stock was trading at $3.95 at the beginning of 2023. Since then, SANA shares have increased by 19.2% and is now trading at $4.71. View the best growth stocks for 2023 here. When is Sana Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023. View our SANA earnings forecast. How were Sana Biotechnology's earnings last quarter? Sana Biotechnology, Inc. (NASDAQ:SANA) posted its earnings results on Sunday, November, 7th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.03. When did Sana Biotechnology IPO? (SANA) raised $322 million in an initial public offering on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO. What is Sana Biotechnology's stock symbol? Sana Biotechnology trades on the NASDAQ under the ticker symbol "SANA." Who are Sana Biotechnology's major shareholders? Sana Biotechnology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (5.64%), Clarius Group LLC (0.02%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christian Hordo, James J Macdonald and Patrick Y Yang. View institutional ownership trends. How do I buy shares of Sana Biotechnology? Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sana Biotechnology's stock price today? One share of SANA stock can currently be purchased for approximately $4.71. How much money does Sana Biotechnology make? Sana Biotechnology (NASDAQ:SANA) has a market capitalization of $898.34 million. The company earns $-355,930,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. How many employees does Sana Biotechnology have? The company employs 383 workers across the globe. How can I contact Sana Biotechnology? Sana Biotechnology's mailing address is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. The official website for the company is sana.com. The company can be reached via phone at 206-701-7914 or via email at investor.relations@sana.com. This page (NASDAQ:SANA) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.